The DOCK5 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population with disrupted DOCK5 gene expression in the Raji B lymphocyte line. This heterogeneous pool provides a loss-of-function model to study DOCK5-dependent processes without clonal selection biases, enabling robust analysis of signaling and cytoskeletal dynamics.
Derived from a Burkitt’s lymphoma patient, the Raji cell line is EBV-positive and grows in suspension. It is widely employed in immunological research, modeling B cell receptor (BCR) signaling, lymphomagenesis, and apoptosis, while retaining key B cell markers and functional pathways relevant to both normal and malignant B cell biology.
DOCK5 encodes a guanine nucleotide exchange factor (GEF) that activates Rac1 and Cdc42 by promoting GTP binding. Downstream, this triggers PAK kinases and the WAVE complex to drive actin polymerization and cell migration. Upstream, integrin engagement and receptors such as PDGFR recruit adaptor proteins Crk and Nck, which interact with DOCK5 and its cofactors ELMO1/2. The resulting signaling cascade??PDGFR ?? Crk/DOCK5 ?? Rac1 ?? PAK ?? WAVE ?? actin remodeling??regulates cell migration, invasion, and myoblast fusion, with implications in cancer metastasis.
In the Raji B cell context, DOCK5 likely modulates actin dynamics downstream of BCR and integrin signals, influencing cell adhesion, migration, and potentially lymphoma cell dissemination. Disrupting DOCK5 in these cells allows dissection of its role in B cell activation and lymphomagenesis, and provides a comparative model for DOCK5-related pathologies such as breast cancer and osteoporosis.
This knockout cell pool supports diverse assays: Western blotting for DOCK5 and phospho-PAK, Rac1 GTPase activation assays, Transwell migration/invasion studies, phalloidin staining for F-actin, flow cytometry for B cell markers (e.g., CD19, CD20), and drug sensitivity screens. It is ideal for investigating Rac1-mediated migration in B cell malignancies and high-throughput anti-metastatic compound screening. For further details, contact Ascent Research.
